cyrilzakka/clinical-trials huggingface dataset:
Detachable String Magnetically Controlled Capsule Endoscopy for Completely Viewing of Esophagus and Stomach

The purpose of the study is to determine the safety and feasibility of the new technique,detachable string magnetically controlled capsule endoscopy(DS-MCE)for evaluating gastric and esophagus diseases.

Esophageal capsule endoscopy(ECE)provides a novel noninvasive approach to visualize the esophagus.The main drawback for the use of ECE is its unreliable transit time which often renders an inadequate visualization of the esophagus.Thus investigators have developed the detachable string magnetically controlled capsule endoscopy(DS-MCE) which can control the movement of the capsule through the string.

This study is a prospective, single-centered, self-controlled pilot study.Outpatients who have esophagus symptoms will take conventional endoscopy examination and DS-MCE successively.

Eligibility Criteria:
Inclusion Criteria:

* outpatients who have esophagus symptoms.

Exclusion Criteria:

* known or suspected complex history of gastrointestinal obstruction, stenosis or fistula.
* dysphagia or delayed gastric emptying.
* known or suspected possibility of active bleeding of digestive tract.
* a history of abdominal operation.
* pacemaker implantation and gastrointestinal pacemaker users.
* patients who are allergic to simethicone or pronase.
* pregnant women,mental patients.
* other circumstances that doctors consider inappropriate for the study.
Patient-Centered Tablets: Applications for Inpatient Admissions

RESEARCH QUESTION:

Are hospitalized patients able to use a tablet computer (iPad) to take brief surveys, access their patient portal (MyChart), and watch informational videos about their condition?

STUDY DESIGN:

Small pilot study evaluating pre/post impressions of information technology and the feasibility of using a tablet computer for education purposes and to complete a daily survey about preparations for discharge and post-acute care.

The study has two distinct parts. Patients will have the option to participate in either one or both parts.

PART 1: Using iPads to learn about health conditions We will enroll and randomize patients to intervention or control groups. Allocation to be intervention or control group will be determined using a computer-based random number generator. All patients will be orientated to using an iPad, asked to take a pre-use survey, will have a MyChart account set up and view EMMI modules. Intervention group patients will receive specific detailed education about how to access, navigate and use MyChart using tablets (iPads) . Control group patients will not receive this specific education about how to access, navigate and use MyChart using tablets (iPads). Both intervention and control group patients will be asked to complete a post-use survey. We will access MyChart data repositories to determine if patients continue to access their patient portal for up to 30 days after the completion of this part of the study.

PART 2: Using iPads to prepare for discharge We will enrol all eligible patients (regardless of intervention or control group status in Part 1) to complete a daily Readiness for Discharge Survey (RDS). This standardized validated survey will determine a range of discharge and post-acute issues and will be fed back to the patient's health care team. Patient demographic and clinical information will be abstracted from their medical record to determine if there are any specific issues related to specific groups of patients. Initially the RDS will be completed on a paper survey but will be eventually be administered via an iPad.

Eligibility Criteria:
Inclusion Criteria:

Adult patients admitted to any service at UCSF Medical Center

Exclusion Criteria:

Patients not speaking English. Patients unable to give consent. Patients unable to safely use a tablet computer for any reason. Patients being discharged on day of approach. Patient cognitively impaired and unable to give consent. Patient in ICU. Patient in some form of droplet isolation.
Phase I Study of Tin Mesoporphyrin in Patients on Long Term Heme Therapy for Prevention of Acute Attacks of Porphyria

OBJECTIVES: I. Evaluate the effectiveness of tin mesoporphyrin in reducing the number of heme infusions needed to prevent acute attacks of porphyria.

II. Evaluate the safety and tolerability of tin mesoporphyrin in these patients.

PROTOCOL OUTLINE: This is an unblinded study. Patients start a preventive heme regimen and are followed for 6 months prior to tin mesoporphyrin. The frequency of attacks is recorded.

Patients receive tin mesoporphyrin once a week for 6 months. Patients must avoid sunlight during treatment and for 2 months thereafter. The frequency of heme infusions is reduced by half and the frequency of attacks of porphyria is monitored.

Patients are followed for 6 months after last treatment.

Eligibility Criteria:
PROTOCOL ENTRY CRITERIA:

--Disease Characteristics-- Documented acute intermittent porphyria, variegate porphyria, or hereditary coproporphyria causing 6 or more attacks per year Fewer than 2 attacks in the preceding 6 months if already on preventive heme therapy --Prior/Concurrent Therapy-- See Disease Characteristics --Patient Characteristics-- Performance status: Not specified Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Urinary porphobilinogen at least 20 mg/24 hours during acute symptoms Other: Not pregnant Fertile female patients must use effective contraception during and for 6 months prior to study No recurrent symptoms due to another illness No continuous (for longer than 1 month) symptoms of porphyria unless it is in addition to acute exacerbations No acute hemorrhagic disorder such as: Gastrointestinal bleeding Intracerebral hemorrhage No known hypersensitivity to tin mesoporphyrin No known hypersensitivity to any intravenous heme preparation No other condition which may increase risk to patient
Aim 1: App for Reducing Cravings to Smoke

The aim of this study is to update a recently developed study-related smartphone application to reduce cravings to smoke to be an engaging, user-friendly treatment tool, and verify user satisfaction


Eligibility Criteria:
Inclusion Criteria:

* \>18 years of age
* Daily smokers that have quit smoking within the past 3 months (Aim 1) or currently smoking ≥ 3 cigarettes per day for the past year (Aim 2)
* Functioning telephone number
* Owns a smart phone capable of supporting AR and willing to download the app
* Can speak, read and write in English

Exclusion Criteria:

* Has another household member already enrolled in the study
Treatment of Adult Traumatic Rib Fractures With Percutaneous Cryoneurolysis

The purpose of this research study is to examine the effectiveness of using the Iovera Smart Time 190, for ultrasound-guided cryoneurolysis, in trauma patients 18-64 years old with rib fractures that are not candidates for surgical stabilization. This will offer patients the benefits of cryoneurolysis of the intercostal nerves, thereby providing short and long term pain control while their ribs heal.

The Iovera Smart Tip 190 is FDA approved for cryoneurolysis.

The purpose of this research study is to examine the effectiveness of using the Iovera Smart Time 190, for minimally invasive ultrasound-guided cryoneurolysis, in trauma patients 18-64 years old with rib fractures that are not candidates for surgical stabilization. This procedure will offer patients the benefits of cryoneurolysis (freezing) of the intercostal nerves, thereby providing short and long term pain control while their ribs heal.

Patients in the intervention arm will receive cryoneurolysis via the Iovera device and patients in the control arm will receive standard of care which typically includes multimodal pain therapy and pulmonary toilet. Short and long term pain relief will be compared among both arms.

Eligibility Criteria:
Inclusion Criteria:

* Patients 18 to 64 years with any acute rib fracture between rib 3 and rib 9
* Pain score equal to or greater than 5 with deep inspiration
* Presenting and admitted to Stanford Adult Emergency Department, having a trauma consult, and being admitted to the trauma floors of Stanford Healthcare (SHC) for their inpatient stay

Exclusion Criteria:

* Radiographic evidence of metastasis to ribs
* Glasgow Coma Scale (GCS) score \<13
* Patients undergoing SSRF (Surgical stabilization of rib fractures)
* Rib fractures located \< 3cm from spinous process
* Coagulopathy (INR \>1.5, Plt \< 100)
* Other factors precluding cryoneurolysis at the attending's discretion
* If only ribs broken are 1,2 or 10,11,12
* Inability to be positioned for the procedure
* If the patient has the following conditions that the manufacturer of the Iovera device advises AGAINST using the device if present: Cryoglobulinemia, Paroxysmal cold hemoglobinuria, Cold urticaria, Raynaud's disease, open and/or infected wounds at or near the treatment site.
A Pilot Study to Evaluate the Effect of Pomegranate Juice on Semen Parameters in Healthy Male Volunteers

How daily consumption of pomegranate juice affects the concentration, morphology or motility of sperm in healthy men.

To determine, in this pilot study, whether daily consumption of pomegranate juice (POM) affects the concentration, morphology or motility of sperm in healthy men. The purpose of the present pilot study is to examine the hypothesis that POM may improve semen parameters in men.

Eligibility Criteria:
Inclusion Criteria:

* 12 healthy men aged 18-40
* normal sperm counts

Exclusion Criteria:

* History of undescended testes or surgery to the scrotal contents,
* History of marijuana or alcohol abuse, hot tub usage at least 3 months prior to entry into the study
* No alpha adrenergic medications within two weeks of entry into the study,
* No anabolic steroid use,
* No anticholinergic or antimuscarinic drugs, use of colchicine, cimetidine, sulfasalazine, antipsychotics, antidepressants, immunosuppressive drugs prior use of any chemotherapeutic drugs, or UTI on screening visit.
Cord Blood Transplantation in Patients With Advanced Lymphoid Malignancies

Indication: Patients with advanced lymphoid malignancies in the absence of an HLA identical or mismatch donor.

Objectives: Overall survival at one year. Efficacy \>60%, rejection rate \<20%. Inclusion criteria: Age: 18-65 years old, no sibling or unrelated donor identified, low grade non-hodgkin lymphoma in third line (who already received at least one autologous transplantation); hodgkin lymphoma in early relapse (\<1 year), who received at least one autologous transplantation and sensible to chemotherapy and CLL with 17p deletion or in relapse less than 2 year after a fludarabine nbased regimen or in relapse after one autologous transplantation.

Stem cell source: Two cord blood units containing both together more than 3x107 frozen nucleated cells/Kg with no more than 2 out of 6 HLA mismatches between them and with the patients.


Eligibility Criteria:
Inclusion Criteria:

* Age: 18-65 years old
* no sibling or unrelated donor identified (9/10 or 10/10)
* with either one of these advanced lymphoid malignancies

  1. low grade non-hodgkin lymphoma in third line (who already received at least one autologous transplantation)
  2. hodgkin lymphoma in early relapse (\<1 year)who received at least one autologous transplantation and sensible to chemotherapy
  3. CLL with 17p deletion or in relapse less than 2 year after a fludarabine nbased regimen or in relapse after one autologous transplantation.

Exclusion Criteria:

* No patient signed consent
* Previous allograft
* Psychiatric conditions
* HIV positive
* HVC hepatitis requiring treatment
* Previous total body irradiation (TBI)
* Any contraindication to TBI
* Any contraindication to allograft, such as cardiovascular, respiratory, renla or liver dysfunctions
* No Health care insurance
Behavioral Activation for Perinatal Depression

This pilot study will examine the feasibility, acceptability, and effectiveness of a brief behavioral activation psychotherapy for women with perinatal depression.


Eligibility Criteria:
Inclusion Criteria:

- Pregnant PHQ9 Depression Score of 15 or greater Receiving prenatal care at one of the participating sites

Exclusion Criteria:

- Known diagnosis of bipolar or psychotic disorder Active substance dependence Immediate risk of self harm Immediate need for inpatient mental health treatment
The Effect of Epidural Anesthesia on the Optic Nerve Sheath Diameter in Preeclampsia

This study aims to assess the effect of epidural anesthesia on the optic nerve sheath diameter in parturients with preeclampsia.

This prospective observational study will be performed in parturients, either with or without preeclampsia, who scheduled to undergo elective cesarean delivery under epidural anesthesia. Epidural anesthesia will be done according to the standard technique. Optic nerve sheath diameter (ONSD) will be measured before and after the epidural injection of anesthetic solutions using ultrasonography. The investigators will assess whether epidural anesthesia has effect on optic nerve sheath diameter of pregnant women, and the investigators will also compare ONSD between healthy parturients and parturients with preeclampsia. The investigators will evaluate the relationship between ONSD and disease severity of preeclampsia.

Eligibility Criteria:
Inclusion Criteria:

* Patients scheduled to undergo planned cesarean section under epidural anesthesia if they have a singleton pregnancy, complicated by severe preeclampsia.

Severe preeclampsia was defined using the American College of Obstetricians and Gynecologist Task Force on Hypertension in Pregnancy recommendations

* Controls will be healthy pregnant women at term (\>37 weeks), with a singleton pregnancy, no signs or symptoms of preeclampsia and no intrauterine fetal growth restriction, who are planned to undergo elective cesarean delivery under epidural anesthesia

Exclusion Criteria:

* Contraindication to epidural anesthesia
* Morbid cardiovascular disease
* Cerebrovascular disease
* Known fetal anomaly
* Any signs of onset of labor
* Body weight \< 40 kg or body weight \> 100 kg
* Height \< 140cm or height \> 190cm
* eye disease
* infection or trauma near the eyes
* abnormality of intracranial pressure due to Intracranial pathology
One Day Implantation Program for Heart Failure Patients Implanted With CRT-P

This study has been implemented to evaluate cardiac resynchronization therapy pacemaker (CRT-P) implantations on a same-day basis

The objective of the study is to show in the French centers selected for the same-day organization that a same-day CRT-P implantation is safe, feasible, and associated with significant cost-saving and a minimum conversion rate to full hospitalization by comparing outcomes with patients routinely hospitalized for at least one night. The medical economic evaluation will be based on the SNDS (National Health Data System) analysis.

Eligibility Criteria:
Inclusion Criteria:

* Planned de novo implantation or upgrade to a Cardiac Resynchronization Therapy Pacemaker system according to the intended use
* Patient is able to understand the nature of the registry and has provided written informed consent for BIO\|STREAM.HF (heart failure registry) and the registry-based trial BIO\|OEDIPE.CRT-P
* Patient enrolled in BIO\|STREAM.HF (heart failure registry)

Exclusion Criteria:

* Patients in emergency situation or without medical assessment before hospitalisation for implantation
* Patients previously implanted with an implantable cardiac defibrillator system
* Patients with an implantable cardiac defibrillator indication
* Patients planned to be implanted with an epicardial left ventricular lead (not implanted via the coronary sinus)
* Patients planned to be implanted with His bundle pacing system
Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site

In this randomized trial, we will investigate the activity and toxicity of two active regimens, gemcitabine/irinotecan and paclitaxel/carboplatin/Etoposide (both followed by ZD1839) in the first-line treatment of patients with carcinoma of unknown primary site.

Upon determination of eligibility, all patients will be randomly assigned to one of two treatment arms:

* Paclitaxel + Carboplatin + Etoposide
* Irinotecan + Gemcitabine

Patients will be stratified by tumor location (liver/bone versus all others) and number of metastatic sites (one versus two or more). Patients with an objective response or stable disease after completion of chemotherapy will receive ZD1839 until disease progression. Patients who do not respond to chemotherapy may crossover to the other chemotherapy regimen and will receive ZD1839 if they have an objective response or stable disease. The study is not blinded so both the patient and the doctor will know which treatment has been assigned.

Eligibility Criteria:
Inclusion Criteria:

To be included in this study, you must meet the following criteria:

* Carcinoma of unknown primary site
* Biopsy-proven metastatic carcinoma
* Able to perform activities of daily living with minimal assistance
* No previous treatment with any systemic therapy
* Measurable or evaluable disease
* Adequate bone marrow, liver and kidney function
* Understand the nature of this study and give written informed consent

Exclusion Criteria:

You cannot participate in this study if any of the following apply to you:

* Age \< 18 years
* Uncontrolled brain metastases and meningeal involvement
* Other uncontrolled malignancies
* Women pregnant or lactating
* Recent history of significant cardiovascular disease
* Severe or uncontrolled systemic disease
* Other significant clinical disorder
* Clinically active interstitial lung disease

Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.
Efficacy of Well-Being Promotion Program for Management of Emotional and Behavioural Problems Among Adolescents

The objectives of the study are given as under;

1. To examine the efficacy of the Well-being Promotion Program in enhancing subjective well-being, positive affect, life satisfaction and reducing emotional /behavioral problems , negative affect among adolescents with emotional and behavioral problems.
2. To examine the differences in terms of subjective well-being, emotional / behavioral problems , positive / negative affect and life satisfaction between the treatment and control group after intervention.
3. To examine the differences in terms of subjective well-being, emotional / behavioral problems, positive / negative affect and life satisfaction in the intervention group at (T1) before and at (T2) after intervention.

In this study, adolescents within age range ( 14-19years) will participates in the study because this study focus on the emotional and behavioral problems and their low level of well-being and life satisfaction among adolescents. Adolescence is a developmental period in which dramatically emotional changes occur which may be the result of biological changes such as secretions of hormones. Chances of psychological distress are increased due to emotional changes. Depression and anxiety are most common psychopathology in adolescents (Ma \& Fang, 2019). Child turns out to be independent, gradually deals with the external world and starts taking his/her decisions such as selection of subjects, peer pressure and so on. Thus , it is important to focus on mental health and management of emotional and behavioral problems.

Eligibility Criteria:
Inclusion Criteria:

* Inclusion Criteria Only those participants who meet the category of moderate level of emotional and behavioural problems through Strength and difficulty Questionnaire (SDQ; Urdu Version) (Samad et al., 2005) will be selected for the study.

Exclusion Criteria:

* Exclusion Criteria Those participants who meet high levels of emotional and behavioural problems through Strength and difficulty Questionnaire (SDQ; Urdu Version) (Samad et al., 2005) will not be selected for the study.
The Effect of Enhanced Recovery After Surgery (ERAS) in Gastric Cancer Surgery

The investigators aimed to clarify the clinical relevance of the ERAS protocol by evaluating the perioperative course in patients undergoing laparoscopic gastric cancer surgery.

Gastric cancer is 7th common malignant disease in Taiwan, accounting for 3000 new cases per year. The main treatment of gastric cancer is radical gastrectomy and lymph nodes dissection, which is associated with 13.0\~46 % of surgical morbidities. To minimize the surgical morbidities and enhance patients' recovery, perioperative management is mandatory. Enhanced Recovery After Surgery (ERAS) is a multimodal, multidisciplinary approach to the care of the surgical patient. ERAS process implementation involves a team consisting of surgeons, anesthetists, an ERAS coordinator, and staff from units that care for the surgical patient. The main elements of ERAS include carbohydrate loading before surgery, minimally invasive approaches, balanced management of intravenous fluids, multimodal pain management, early mobilization, and early oral feeding, etc. Some prospective studies have shown its effectiveness in reduce surgical morbidity and hospital stay in colorectal surgery. In Taiwan, there was only limited report to study the use of ERAS in gastric cancer surgery. The investigators would like to integrate these perioperative interventions into the ERAS program, and test its effectiveness in gastric cancer patients undergoing radical gastrectomy at NTUH.

Eligibility Criteria:
Inclusion Criteria:

* Pathological confirmed as gastric adenocarcinoma;
* Gastric cancer patients who will undergo subtotal gastrectomy.

Exclusion Criteria:

* Advanced gastric cancer with gastric outlet obstruction;
* Epidural catheter placement contraindicated or inexecutable;
* Have other cancers that have received chemotherapy or radiation therapy;
* Coagulation abnormalities;
* Pregnancy;
* Severe dysfunction of major organs (e.g., heart failure, chronic obstructive pulmonary disease, liver cirrhosis, end-stage renal disease)